Pore-Forming Polyene Macrolides Restore Ion Flow in Cystic Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cystic fibrosis, caused by mutations in the CFTR gene leading to reduced function of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, results in chronic respiratory infections and pancreatic insufficiency, with current treatments only providing symptomatic relief and limited median survival of 33 years.
Innovation Solution
Administration of a therapeutically effective amount of a pore-forming polyene macrolide, such as amphotericin B (AmB) or its derivatives, to facilitate transmembrane trafficking of ions regulated by the CFTR ion channel, thereby treating conditions characterized by decreased expression or reduced function of the ion channel.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CFTR ion channel function is restored using small molecule mimics, then ion transport defects are corrected and physiology is improved, but the complexity of treating channelopathies increases
Solution Approach 1:
The patent uses small molecule mimics that copy the functional properties of the CFTR ion channel without requiring the actual protein. These molecules replicate the channel's ion transport capability, allowing restoration of physiology in CFTR-deficient cells. This copying approach simplifies the treatment by using small molecules instead of complex protein replacement therapies.
Solution Approach 2:
The small molecule mimics act as intermediary substances that mediate ion transport in place of the defective CFTR channel. These intermediaries bind to and activate existing ion channels or create functional equivalents, serving as a bridge between the therapeutic goal and the cellular machinery, thereby avoiding the need for direct CFTR protein restoration.
2Productivity
If pore-forming polyene macrolides are administered to restore ion flow, then transmembrane ion trafficking is improved, but potential toxicity effects may occur
Solution Approach 1:
The patent optimizes the concentration parameters of pore-forming polyene macrolides to achieve therapeutic effect while minimizing toxicity. By carefully controlling the dose and duration of administration, the treatment achieves sufficient ion transport restoration without reaching toxic thresholds. This parameter optimization allows the same molecule to serve both therapeutic and safety requirements.
Solution Approach 2:
The patent applies partial action by using sub-toxic concentrations of polyene macrolides that are sufficient to restore ion transport but do not cause harmful effects. Rather than using high doses that would definitely produce toxicity, the treatment uses just enough partial action to achieve the therapeutic goal, thereby avoiding the harmful effects of excessive action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AmB, at non-toxic nanomolar concentrations, permeabilizes both yeast cells and human lung epithelia, restoring ion flow and airway surface hydration, potentially addressing the underlying ion transport defects in cystic fibrosis and other channelopathies.
Implementation Method 1
The pore-forming polyene macrolide or pore-forming derivative thereof permits transmembrane trafficking of ions otherwise regulated by the ion channel
Implementation Method 2
Normally, the protein moves chloride and thiocyanate ions (with a negative charge) out of an epithelial cell to the covering mucus. Positively charged sodium ions follow passively, increasing the total electrolyte concentration in the mucus, resulting in the movement of water out of the cell by osmosis
Data Source
AI summary
Disclosed are methods for treating a disease or condition characterized by decreased expression or reduced function of an ion channel, comprising administering to a subject in need thereof a therapeutically effective amount of a pore-forming polyene macrolide or pore-forming derivative thereof. For example, the pore-forming polyene macrolide may be amphotericin B (AmB), nystatin, or natamycin. The methods can be used to treat cystic fibrosis.